Summary
A Swedish case-control study found that a specific sugar-modified form of CA-125 was associated with ovarian cancer diagnosed several years later. The preprint suggests a possible early-risk signal, but larger studies using repeated samples are needed.
A specific sugar-modified form of the ovarian-cancer biomarker CA-125 was associated with cancer diagnosed several years later in a Swedish case-control study, according to a medRxiv preprint posted on September 14, 2026. The signal remained predictive in analyses reaching roughly five to seven years before clinical diagnosis, while conventional CA-125, HE4 and another tested CA-125 glycovariant showed little meaningful prediction.
The finding points to a possible way of extracting more information from CA-125 than its total concentration alone. It is an early research result, not a validated population-screening test.
A different signal from CA-125
CA-125 is a blood biomarker associated with ovarian cancer. The preprint notes that two randomized trials found that screening with conventional CA-125 did not reduce ovarian-cancer mortality. The authors suggest that one reason may be that changes in the overall CA-125 level occur too late for surgery to cure early-stage disease.
The new study examined glycovariants: forms of the same protein that differ in their attached sugar structures. The researchers measured the CA-125 glycovariant Sialyl-Thomsen-nouveau, abbreviated CA-125-STn, along with a second CA-125 glycovariant detected using a Macrophage-Galactose-Lectin, or MGL, assay. Conventional CA-125 and HE4 were measured for comparison.
What the Swedish study measured
The researchers used stored blood samples and health-record data from the population-based Malmö Diet and Cancer cohort in Sweden. Samples collected at baseline between 1991 and 1996 were available for 17,297 women aged 44 to 73. A further 2,168 women were re-sampled between 2007 and 2012.
The researchers linked participants to the Swedish cancer registry and identified 82 women who developed ovarian cancer up to 10 years after blood collection. Each case was matched with three controls according to age and the date of blood collection, producing a case-control analysis of the biomarker measurements.
The primary analysis focused on cases diagnosed within five years of the blood draw. CA-125-STn was associated with subsequent ovarian cancer, with a reported p-value of 0.002. Its area under the receiver-operating-characteristic curve was 0.68 in this analysis. As a general measure, an area under the curve of 0.5 represents no discrimination between cases and controls, while 1.0 represents perfect separation; 0.68 indicates a measurable but incomplete distinction.
The early signal and its limits
Among women whose cancer was diagnosed within five years, 27% of cases had CA-125-STn levels in the highest 5% of the measured distribution. The threshold for that group was at least 2.3 U/ml. The highest 10% contained 35% of these cases, and the highest 20% contained 49%.
A moving-window analysis suggested that the association remained predictive as far as five to seven years before diagnosis. The result was also reproduced through independent measurements of a separate sample aliquot in a subset of cases and controls.
Because the study used a case-control design, these percentages describe how cases were distributed among biomarker-level groups in the research cohort. They are not results from a prospective screening programme and do not show whether using the marker would reduce deaths, detect more curable cancers or improve treatment outcomes.
The study found no important prediction from conventional CA-125, HE4 or the MGL-detected CA-125 glycovariant. The authors propose larger cohorts with sequential blood samples to define how CA-125-STn changes as risk approaches diagnosis and to test whether combining it with other markers improves prediction.
The report is a preprint. Its authors also disclose that some researchers are named on a patent application involving CA-125 glycovariants for ovarian-cancer prediction, while several authors work for Uniogen, which supplied the GLYVAR Ovarian I and II assays. These disclosures are relevant as the marker moves toward independent evaluation in larger, longitudinal studies.